Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A post hoc analysis of a 32-week randomised trial examined how semaglutide, empagliflozin and their combination altered renal diffusion-weighted MRI and total kidney volume in type 2 diabetes. PICO summary and expert commentary.
PIONEER 12 was a 26-week double-blind Phase IIIa trial showing all three doses of once-daily oral semaglutide lowered HbA1c and body weight more than sitagliptin 100 mg in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.
Phase IIIa double-blind trial of oral semaglutide monotherapy vs placebo in a predominantly Chinese type 2 diabetes population, with HbA1c and body-weight findings. PICO summary and expert commentary.
A single-centre RCT (n=180) testing an integrated cloud data platform with dietary management and education videos against routine care in type 2 diabetes, with HbA1c lower at 12 weeks. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN 6 trial reports that once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease in adults with type 2 diabetes who had no kidney disease at baseline. PICO summary and expert commentary.
A 12-week pilot RCT comparing an 800 kcal/day very-low calorie diet, semaglutide, and their combination in 30 adults with type 2 diabetes. PICO summary and expert commentary.
A small single-centre study found that adding a long-acting GLP-1 receptor agonist to metformin lowered BMI but did not show a significant between-group glycaemic advantage. PICO summary and expert commentary.
How patient and public involvement shaped the design of ASCEND PLUS, a decentralised RCT of oral semaglutide for cardiovascular prevention in type 2 diabetes. PICO summary and expert commentary.
A 32-week post hoc MRI substudy of 80 patients with type 2 diabetes finds semaglutide and empagliflozin each reduce cortical ADC and total kidney volume, with combination therapy lowering kidney volume most. PICO summary and expert commentary.
PIONEER 12 was a 26-week, double-blind, manufacturer-sponsored Phase IIIa trial showing oral semaglutide lowered HbA1c and body weight more than sitagliptin in a predominantly Chinese population with type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
